Spots Global Cancer Trial Database for RT Plus EGFR-TKI for Wild-type NSCLC

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: RT Plus EGFR-TKI for Wild-type NSCLC

Official Title: Thoracic Radiotherapy Combined With EGFR-TKI for Wild-type Non-small Cell Lung Cancer

Study ID: NCT02738983

Conditions

Non-small Cell Lung Cancer

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)

Interventions

Erlotinib (trade name: Tarceva®) or Icotinib (trade name: Conmana®)

Radiotherapy

Study Description

Brief Summary: Concurrent chemoradiotheray is the standard care for patients with locally advanced non-small cell lung cancer (NSCLC), but often accompanying with high toxicity and poor tolerability. Radiosensitization of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) has been proved in preclinical studies, and the safety of TKI combined with thoracic radiotherapy has also been evaluated in several phase II trials. The aim of study is to investigate the efficacy and safety of thoracic radiotherapy combined with TKI in wild-type EGFR patients who refused or unsuitable for concurrent chemoradiotherapy.

Detailed Description: